Barasch D, Zipori O, Ringel I, Ginsburg I, Samuni A, Katzhendler J
Department of Pharmaceutical Chemistry, The Hebrew University of Jerusalem, 91120, Jerusalem, Israel.
Eur J Med Chem. 1999 Jul-Aug;34(7-8):597-615. doi: 10.1016/s0223-5234(00)80029-x.
The mode of action of antitumour anthraquinone derivatives (i.e. mitoxantrone) is not clearly established yet. It includes, among others, intercalation and binding to DNA, bioreduction and aerobic redox cycling. A series of anthraquinone derivatives, with potentially bioreducible groups sited in the side chain, have been synthesized and biologically evaluated. Their redox and cytotoxic activities were screened. Derivatives which bear a 2-(dimethylamino)ethylamino substituent, known to confer high DNA affinity, demonstrated cytotoxicity but not redox activity (beside the anthraquinone reduction). Conversely, derivatives which showed redox activity were not cytotoxic toward the P388 cell line. The results suggest that bioreduction is not the main mode of action in the cytotoxicity of anthraquinones.
